We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$6.95M
Cap. Flow
-$1.04M
Cap. Flow %
-0.83%
Top 10 Hldgs %
37.72%
Holding
74
New
9
Increased
25
Reduced
7
Closed
17
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.42M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.55M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$1.03M
4
PCRX icon
Pacira BioSciences
PCRX
+$949K
5
ARRY icon
Array Biopharma Inc
ARRY
+$886K

Top Sells

Rank Stock Value
1
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.15M
2
PCYC
PHARMACYCLICS INC
PCYC
+$3.48M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.73M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$912K
5
TENX icon
Tenax Therapeutics
TENX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 82.86%
2 Miscellaneous 16.89%
3 Financials 0.25%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KBIO
51
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$358K 0.28%
93,308
– –
2014 Q4
2 quarters
NHLD
52
DELISTED
National Holdings Corporation
NHLD
$321K 0.25%
89,530
– –
2015 Q1
1 quarter
JUNO
53
DELISTED
Juno Therapeutics, Inc.
JUNO
$267K 0.21%
+5,000
New +$265K
2015 Q2
0 quarters
ARRY icon
54
CALL
DELISTED
Array Biopharma Inc
ARRY
$135K 0.11%
+2,000
New +$14.8K
2015 Q2
0 quarters
JUNO
55
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
$49K 0.04%
+50
New +$2.65K
2015 Q2
0 quarters
NEPT
56
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
0
– –
2015 Q1
1 quarter
ADVM icon
57
DELISTED
Adverum Biotechnologies
ADVM
– –
-1,000
Closed -$405K –
AGIO icon
58
Agios Pharmaceuticals
AGIO
$1.93B
– –
-5,000
Closed -$472K –
BLUE icon
59
DELISTED
bluebird bio
BLUE
– –
-463
Closed -$725K –
KPTI icon
60
Karyopharm Therapeutics
KPTI
$7.96M
– –
-1,000
Closed -$459K –
LITS icon
61
Lite Strategy Inc
LITS
$36.3M
– –
-1,500
Closed -$54K –
MGNX icon
62
MacroGenics
MGNX
$215M
– –
-15,000
Closed -$471K –
OMER icon
63
Omeros
OMER
$1.36B
– –
-20,000
Closed -$441K –
TENX icon
64
Tenax Therapeutics
TENX
$56.5M
– –
-8
Closed -$812K –
XNCR icon
65
Xencor
XNCR
$1.78B
– –
-44,698
Closed -$685K –
EIGR
66
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-94
Closed -$803K –
MRTX
67
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-25,000
Closed -$733K –
OTIC
68
DELISTED
Otonomy, Inc.
OTIC
– –
-12,000
Closed -$424K –
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
– –
-20,000
Closed -$627K –
MNTA
70
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-60,000
Closed -$912K –
GEVA
71
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-17,700
Closed -$1.73M –
PCYC
72
DELISTED
PHARMACYCLICS INC
PCYC
– –
-13,600
Closed -$3.48M –
SLXP
73
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-24,000
Closed -$4.15M –
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opus Point Partners Management held 74 positions worth $126M, up 5.8% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opus Point Partners Management's Q2 2015 filing shows 9 new, 25 increased, 7 reduced and 17 closed positions. Its largest new stake was AstraZeneca: 50,000 shares worth $3.19M. The largest sale was SALIX PHARMACEUTICALS LTD DEL, an estimated $4.15M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.

  • Opus Point Partners Management's largest Q2 2015 buy was AstraZeneca: 50,000 shares worth $3.19M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2015, an estimated $1.55M increase.
  • Opus Point Partners Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $307K.
  • Opus Point Partners Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $4.15M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $126M portfolio in Q2 2015.
  • Opus Point Partners Management opened 9 new positions and closed 17 in Q2 2015.
  • Opus Point Partners Management's portfolio value rose 5.8% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.